Oncology and Carcinogenesis articles for Netherlands

Time frame: 1 July 2025 - 30 June 2026

View topic

Count: 241

Article ‘Count’ for Oncology and Carcinogenesis.

Journal Count Share
1 0.94
Inter-Spheroid Proximity and Matrix Remodeling Determine Cancer Associated Fibroblast Mediated Cancer Cell Invasion 0.94
1 0.03
Preventing Glioblastoma Relapse by Igniting Innate Immunity through Mitochondrial Stress in the Surgical Cavity 0.03
1 0.07
Plant-Derived Polysaccharide Ultrafast Purification Reinvented: A Green Aqueous Two-Phase System with Deep Eutectic Solvents for Simultaneous Decolorization and Deproteinization 0.07
2 0.06
Multivalent Antibody-Recruiting Molecules for Targeted Immune-Killing of Carbonic Anhydrase IX-Expressing Cancer Cells 0.04
Marker‐Agnostic Tumor Anchoring Chimeras Enable pH‐Gated Immune Engagement 0.03
1 0.67
Antithrombotic Therapy Discontinuation, Bleeding, and Thromboembolic Events in Patients With Cancer During the Last Phase of Life: Insights From Primary Care Records 0.67
2 0.16
Outcomes of Density-Targeted Supplemental Breast Magnetic Resonance Imaging Screening by Breast Cancer Risk: Long-Term Health and Economic Considerations. 0.10
Eligibility and Prognostic Performance of Smoking Duration-Based Versus Pack-Year-Based U.S. National Lung Cancer Screening Criteria Across Racial and Ethnic Groups. 0.06
1 1.00
Trametinib in Adults with Neurofibromatosis Type 1‐Related Symptomatic Plexiform Neurofibromas 1.00
7 3.66
Robotic Pancreatoduodenectomy Carries Greater Risk of Morbidity after Conversion than Laparoscopy: A Propensity Score-Matched Analysis in the E-MIPS Registry. 0.23
Staging Laparoscopy After Neoadjuvant Treatment for Pancreatic Cancer to Prevent Non-Therapeutic Laparotomy: Analysis in the PREOPANC-2 Randomized Trial. 0.98
The International Study Group for Pancreatic Surgery (ISGPS) Definition and Classification of Postpancreatectomy Mortality. 0.02
Impact of Celiac Axis Stenosis in Patients Undergoing Pancreatoduodenectomy and Total Pancreatectomy: International Multicenter Study. 0.29
Impact of Merging two high-volume Centers on Patient Outcome: 1000 Consecutive Pancreatoduodenectomies. 0.98
Recurrence-free Survival as a Surrogate Endpoint for Overall Survival in Resectable Esophageal Cancer: Integrated Analysis of Individual Patient Data From Phase III Trials. 0.15
Surgical Complications in Patients with (borderline) Resectable Pancreatic Cancer after Neoadjuvant Therapy in the PREOPANC-2 Randomized Controlled Trial. 1.00
1 1.00
What shapes satisfaction with daily life participation? Insights into functional outcomes after pediatric bone sarcoma treatment 1.00
6 0.46
MRD-2 in the GHSG HD21 trial assessed by a validated circulating tumor DNA sequencing assay 0.09
Immune biomarkers of increased infection risk in multiple myeloma 0.06
Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences the risk of acute myeloid leukemia 0.01
CPX-351 in Down syndrome–associated myeloid leukemia: results and prognostic factors from the phase 3 ML-DS 2018 trial 0.05
Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results 0.16
The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy 0.09
11 7.75
Patient-led, home-based follow-up for colorectal cancer: the DISTANCE multicentre stepped-wedge cluster-randomised trial 1.00
Surgical Outcomes from Nationwide Implementation of the International Best-Practice for Locally Advanced Pancreatic Cancer (PREOPANC-4) study 0.91
Metastatic Lymph Node Burden and Invasive Tumour Features Inform First Recurrence Patterns After Curative-Intent Resection for Intrahepatic Cholangiocarcinoma 0.05
Management of gastric cancer peritoneal metastasis: International Gastric Cancer Association GCPM Working Group consensus statements 0.15
Presurgical levels of circulating tumour DNA in patients with resectable chemotherapy-naïve colorectal liver metastases: association with multiorgan recurrence and survival in the MIRACLE cohort 1.00
Survival After Pathological Complete Response Following Neoadjuvant Chemotherapy vs Chemoradiotherapy in Esophageal Squamous Cell Carcinoma 0.15
Circulating tumour DNA in patients with stage III colon cancer: multicentre prospective PROVENC3 study 0.72
Health-related quality of life of patients undergoing active surveillance versus standard surgery for oesophageal cancer (SANO trial) 1.00
Nationwide outcomes of 1000 robotic pancreatoduodenectomies across the four phases of the learning curve 1.00
Oncological outcome after robot-assisted versus open pancreatoduodenectomy for upfront resectable cancer in the pancreatic head: a nationwide cohort analysis 0.98
Factors influencing locoregional recurrence rates in locally advanced rectal cancer after total neoadjuvant treatment versus chemoradiotherapy in the RAPIDO trial 0.79
2 0.14
Targeting tumor-intrinsic STK40 induces immune vulnerability and drives T cell reinvigoration 0.03
A longitudinal single-cell atlas to predict outcome and toxicity after BCMA-directed CAR T cell therapy in multiple myeloma 0.11
5 3.77
Targeting the Non-Homologous End Joining Pathway Sensitizes MDM2-Amplified Liposarcoma to Doxorubicin by Enhancing p53-Mediated Senescence 1.00
C-terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3 0.77
Estrogen Production in Pancreatic Cancer Shapes a Tumor Suppressive Stromal Microenvironment. 1.00
Chemotherapy-Treated Breast Cancer Cells Activate the WNT Signaling Pathway to Enter a Diapause-Like Early Persister State. 0.08
Large-scale Characterization of Orthotopic Cell Line–Derived Xenografts Identifies TGFβ Signaling as a Key Regulator of Breast Cancer Morphology and Aggressiveness 0.92
1 0.02
Plasma signals of lung tumor promotion for molecular cancer prevention 0.02
1 0.35
Meta-analysis reveals microbiome signatures for colorectal cancer that are universal across age groups and sequencing methods 0.35
1 0.05
Compartmentalized branched-chain amino acid metabolism orchestrates colorectal cancer dissemination via an UMP-vimentin axis 0.05
1 1.00
Organochloride mediated prodrug activation induced by ionizing radiation 1.00
1 0.12
miR-499 in Platelet-Derived Extracellular Vesicles Augments Inflammatory Cell Generation and Cardiac Remodeling After Myocardial Infarction. 0.12
1 1.00
Effects of a Combined Lifestyle Intervention on Recovery of ICU Survivors: A Randomized Controlled Trial. 1.00
1 0.08
Centrosome clustering in cancer cells requires microtubule assembly through a RanGTP-dependent TPX2-KIFC1 interaction 0.08
3 0.12
Association Between the PRIMARY Score at Staging Prostate-specific Membrane Antigen Positron Emission Tomography and Overall Survival Among Patients with Newly Diagnosed Prostate Cancer: Findings from the International, Multicenter PROMISE Registry 0.04
Development and International Evaluation of an Artificial Intelligence–based Model (PROGRxN-BCa) Using the World Health Organization 2004/2022 Grading System to Predict Progression Risk and Improve Substratification for Non–muscle-invasive Bladder Cancer 0.03
Cost-effectiveness Analysis of Treatments for Bacillus Calmette-Guérin–unresponsive Carcinoma in Situ of the Bladder 0.05
4 1.57
Prevalence and Consequences of APC Mosaicism in Patients With Colorectal Adenomas 0.95
Utility of Serum Biomarkers in Addition to Ultrasound for Early Detection of Hepatocellular Carcinoma in High-Risk Patients: A Randomized Controlled Trial 0.14
Mutational Landscape of Colorectal Tumors From Individuals With Unexplained Adenomatous or Serrated Colorectal Polyposis 0.45
Fecal Detection of Calprotectin Subunits Links Inflammatory Bowel Disease Activity With Chronicity of Intestinal Inflammation 0.02
2 0.38
APOBEC3A drives deaminase mutagenesis in human gastric epithelium 0.05
Comprehensive functional annotation of ESR1-driven enhancers in breast cancer reveals hierarchical activity independent of genomic and epigenomic contexts 0.33
6 0.53
Dual mechanism of immune escape shapes the genetic and immunogenic landscape of mismatch repair-deficient colorectal tumours 0.22
Hepatocellular carcinoma attributable to hepatitis B, hepatitis C and other risk factors at global, regional and national levels: an updated systematic review and meta-analysis 0.11
Stromal biomarker-based framework for identifying pMMR/MSS and dMMR/MSI colorectal cancers with poor outcomes and limited benefit from immunotherapy 0.02
E-cadherin loss in Cd44-positive gastric cells initiates diffuse gastric cancer in a murine model 0.07
Hereditary diffuse gastric cancer spectrum associated with germline iCTNNA1/i loss of function revealed by clinical and molecular data from 351 carrier families and over 37 000 non-carrier controls 0.09
Research priorities for cancers of the oesophagus and stomach: recommendations from a UK and Ireland patient and healthcare professional partnership exercise 0.01
1 0.05
Satellite lesions versus intrahepatic metastasis in multifocal intrahepatic cholangiocarcinoma: Prognostic impact and genomic profiling. 0.05
2 0.33
Nonsense-mediated mRNA decay inhibition reshapes the cancer immunopeptidome 0.01
Immune signature-based uncoupling of checkpoint inhibitor efficacy and toxicity 0.31
2 0.53
The impact of an organized screening program on gastric cancer incidence: a quasi-experimental study 0.46
Investigating the association between anthropometry and colorectal cancer survival: a two-sample Mendelian randomization analysis 0.06
3 0.94
Activity and Physiological Stress Within 90 Days After Minimally Invasive and Open Pancreatoduodenectomy: A Predefined Analysis of the DIPLOMA-2 Randomized Clinical Trial. 0.61
International Reference Values for Surgical Outcomes of Total Pancreatectomy 0.04
Minimally Invasive vs Open Left Pancreatectomy for Resectable Pancreatic Cancer 0.29
1 0.90
Tumor Debulking in Combination With Chemotherapy in Multiorgan Metastatic Colorectal Cancer 0.90
2 0.66
HSP-1-Specific Nanobodies Alter Chaperone Function in vitro and in vivo 0.08
A Modular Uba1-Nanobody Fusion Enables Selective Ubiquitin Transfer to Tagged E2 Enzymes 0.58
1 0.94
Time trends in incidence, treatment, and survival of patients with adrenocortical carcinoma, a nationwide study 0.94
3 0.28
Mutated FGFR1 is an oncogenic driver and therapeutic target in high-risk neuroblastoma 0.04
Personalized treatment in HPV+ oropharynx cancer using genomic adjusted radiation dose 0.08
PTBP1 variants displaying altered nucleocytoplasmic distribution are responsible for a neurodevelopmental disorder with skeletal dysplasia 0.16
14 2.76
Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor–2 Rearrangement: Results From the Phase III FIGHT-302 Trial 0.07
Neoadjuvant Sacituzumab Govitecan in Patients With Muscle-Invasive Bladder Cancer: Primary Results of the SURE-01 Trial 0.04
Overall Survival Among Patients With Hepatocellular Carcinoma Treated With External Beam Radiation Therapy: Individual Patient Data Outcomes From a Multinational Cohort 0.03
Residual Absolute Volume of Blastema as a Predictor of Clinical Outcomes in Patients With Wilms Tumor: A Report From the SIOP WT 2001 Study. 0.14
Impact of Circulating Tumor DNA and Copy-Number Alterations on Clinical Outcome in Relapsed/Refractory Germ Cell Tumors Treated With Salvage High-Dose Chemotherapy. 0.22
Thromboembolic Events During Perioperative Therapy for Resectable and Borderline Resectable Pancreatic Cancer in the PREOPANC-2 Trial. 1.00
Adjuvant Durvalumab in Completely Resected Early-Stage Non-Small Cell Lung Cancer. 0.04
Automated Lymph Node and Extranodal Extension Assessment Improves Risk Stratification in Oropharyngeal Carcinoma. 0.02
Dinutuximab Beta Added to Temozolomide-Based Chemotherapy for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II Trial. 0.04
Hepatic Arterial Infusion Pump Chemotherapy in Patients With Unresectable Intrahepatic Cholangiocarcinoma-PUMP-2 Trial. 1.00
Colorectal-Specific Radiation Dose and Chemotherapy Risk for Subsequent Colorectal Malignancies in Childhood Cancer Survivors: A Childhood Cancer Survivor Study (CCSS) Report. 0.04
Deep Learning Model for Breast Shear Wave Elastography to Improve Breast Cancer Diagnosis (INSPiRED 006): An International, Multicenter Analysis. 0.04
Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial. 0.04
TAR-200 for Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study. 0.04
1 0.36
Hepatic artery infusion pump chemotherapy for unresectable intrahepatic cholangiocarcinoma: Pooled individual patient-level analysis of four clinical trials 0.36
1 1.00
COVID-19 Vaccine Effectiveness in Patients with Hematologic Malignancies: a Nationwide Cohort Study 1.00
1 0.17
Breast cancer cell‐conditioned media inhibit growth and reduce basal and insulin‐stimulated glucose uptake by inhibiting Rac1 activation in rat myotubes 0.17
3 1.98
Modulation of the 14-3-3σ/C-RAF “Auto”inhibited Complex by Molecular Glues 0.47
A Sterically Open Ruthenium-Based Photocage Activated by Red and Far-Red Light for a Wide Range of Drugs 0.73
Structure over States: Planarity, Not Energy, Dictates Photoactivation in Ru(II) PACT Agents 0.79
1 0.93
How to Analyze Longitudinal Patient‐Reported Outcomes in Populations With High Mortality Rates 0.93
20 9.47
Prognostic dynamics of pathological complete response and ctDNA clearance after neoadjuvant/perioperative immunotherapy in cancer: a reconstructed individual patient analysis 0.22
ypTNM versus pTNM staging after neoadjuvant therapy in rectal cancer 0.10
Temporal Trends of Subsequent Malignant Neoplasms in Childhood Cancer Survivors and the Impact of Treatment Changes: A DCCSS-LATER Study 0.98
Change in body mass index and physical activity and postmenopausal breast cancer risk in a cohort of Dutch nurses 0.89
Prediction of resection after preoperative FOLFIRINOX in patients with localized pancreatic adenocarcinoma: a Trans-Atlantic Pancreatic Surgery (TAPS) Consortium study 0.54
The impact of survivorship care on burden of disease among Hodgkin lymphoma survivors 1.00
Menopause-related quality of life 5 years after salpingectomy with delayed oophorectomy vs salpingo-oophorectomy 1.00
Risk of Subsequent Primary Melanoma in 68,002 five-year survivors of childhood and adolescent cancer in Europe: The PanCareSurFup cohort study 0.08
Predicting long-term absolute risk of lung cancer in Hodgkin lymphoma patients 1.00
Restaging after neoadjuvant FOLFIRINOX for localized pancreatic cancer: a clinical calculator from the Trans-Atlantic Pancreatic Surgery consortium 0.46
Weight trajectories throughout adulthood and prostate cancer incidence, aggressiveness, and death in 258,494 men 0.05
Performance of smoking duration-based lung cancer screening eligibility criteria: a comparative modeling study 0.33
Conditional recurrence-free survival after curative esophagectomy: individual patient data analysis of 11 trials 0.15
A smoking-related plasma protein score and smoking-related cancer risk and mortality in ARIC 0.04
Health-related quality of life with first- vs second-line CDK4/6 inhibitor use in advanced breast cancer: results from the SONIA trial 1.00
Stratifying lung adenocarcinoma risk with multi-ancestry polygenic risk scores in East Asian never-smokers 0.01
Assessing the oncologic risk when systematic and multiparametric magnetic resonance imaging-targeted prostate biopsy grade groups are discordant 0.03
Time-varying impact of established prognostic factors in resected pancreatic ductal adenocarcinoma 0.64
Breastfeeding after breast cancer in young iBRCA/i carriers 0.02
The nucleosome remodeling and deacetylase-SWItch/sucrose non-fermentable antagonism regulates the coordinated activation of epithelial-to-mesenchymal transition and inflammation in oral cancer 0.94
1 0.47
A predictor finding study found patient-reported outcomes improve the prediction of mortality of incident dialysis patients 0.47
4 2.42
RNF25 confers mRNA damage tolerance by curbing activation of the integrated stress response 0.08
Cell-surface RNA forms ternary complex with RNA-binding proteins and heparan sulfate to recruit immune receptors 0.89
mTOR signaling during T cell activation promotes cytokine production in T cells through 3′ UTR-mediated translation control 1.00
Condensin II activation by M18BP1 0.45
10 3.91
Acquired genetic and cell-state changes in IDH-mutant glioma progression 0.01
Evolutionary characterization of lung cancer metastasis 0.00
Prospective evaluation of genomics-guided off-label treatment 1.00
Emergence of oncofetal plasticity is ubiquitous in early colorectal cancers 1.00
Thymic health and immunotherapy outcomes in patients with cancer 0.05
Multidimensional profiling of heterogeneity in supratentorial ependymomas 0.01
Neoadjuvant immunotherapy in mismatch-repair-proficient colon cancers 0.88
A missing enzyme-rescue metabolite as cause of a rare skeletal dysplasia 0.13
NASP modulates histone turnover to drive PARP inhibitor resistance 0.79
Respiratory viral infections awaken metastatic breast cancer cells in lungs 0.03
1 0.05
RASH3D19 mediates RAS activation through a positive feedback loop in KRAS-mutant cancer 0.05
34 13.01
Risk stratification and relapse pattern in triple-negative breast cancer with pathological complete response after neoadjuvant treatment: the European GAMBIT real-world study 0.07
Tremelimumab with or without durvalumab in combination with paclitaxel in metastatic urothelial cancer: phase I/II ICRA trial 0.90
A preoperative Artificial Intelligence model to estimate cancer-specific mortality in nonmetastatic kidney cancer patients 0.03
Native long-read RNA sequencing of human monocytes reveals activation-induced alternative splicing toward functional isoforms 1.00
Fusion-positive rhabdomyosarcoma oncofusions share a common interactome 0.31
RBM20 isoform regulation by independent transcription start sites adapts alternative splicing in development and disease 0.06
Near-infrared fluorescence imaging-guided surgery using cRGD-ZW800 to improve surgical resection margins in oral cancer: a phase I/II feasibility trial 0.91
High-depth whole genome sequencing of premalignant breast lesions reveals rearrangement hotspots and personalized management opportunities 0.27
E-cadherin inactivation shapes tumor microenvironment specificities in invasive lobular breast cancer 0.13
Genetic determinants of fatigue up to 2 years after radiotherapy in prostate cancer patients 0.03
Multi-layered molecular profiling informs the diagnosis and targeted therapy of desmoplastic small round cell tumor 0.01
Clinicopathologic and molecular predictors of survival in -deficient tubo-ovarian high-grade serous carcinoma 0.03
Both genome instability and replicative senescence stem from the shortest telomere in telomerase-negative cells 0.19
Intraoperative fluorescence-guided fresh frozen sectioning for margin control in head and neck cancer: phase 2 clinical trial 1.00
A large-scale genome-wide association meta-analysis for nevus count provides direct insights into the genetics of melanoma 0.10
Mast-cell derived nerve growth factor drives ILC2 pro-tumoral functions in bladder cancer 0.03
Inhibition of stress resilience and adult hippocampal neurogenesis by platelet-derived LPA16:0 in anxiety 0.15
NEO-STIM advances personalized neoantigen-specific adoptive T cell therapy 0.33
Site-saturation functional screens identify PALB2 missense variants associated with increased breast cancer risk 0.20
Constitutive activity of an atypical chemokine receptor revealed by inverse agonistic nanobodies 0.58
REACtiVe-2: phase I evaluation of dendritic cell vaccination and agonistic CD40 therapy following (m)FOLFIRINOX in metastatic pancreatic cancer 0.92
Whole-body CD8 T-cell PET imaging in patients with large B-cell lymphoma before and during CD19-directed CAR T-cell therapy: a phase 2 study 0.89
WEE1 inhibitors trigger GCN2-mediated activation of the integrated stress response 0.61
An inflammatory T-cell-stromal axis contributes to hematopoietic stem/progenitor cell failure and clonal evolution in human myelodysplastic syndrome 0.74
A non-canonical lymphoblast in refractory childhood T-cell leukaemia 0.10
Pathogenic variants in cause an X-linked neurodevelopmental disorder modulated by NURF complex composition 0.05
The genomic landscape of relapsed infant and childhood KMT2A-rearranged acute leukemia 0.10
UBE3A promotes foam cell formation and counters remyelination by targeting ABCA1 for proteasomal degradation 0.44
A comparative analysis of heterogeneity in lung cancer screening effectiveness in two randomised controlled trials 0.90
Small round cell sarcoma tumoroid biobank reveals CIC::DUX4 sarcoma vulnerability to MCL-1 inhibition 0.84
Functional avidity of anti-B7H3 CAR-T constructs predicts antigen density thresholds for triggering effector function 0.37
The Helicobacter pylori AI-clinician harnesses artificial intelligence to personalise H. pylori treatment recommendations 0.06
Identification of RNF114 as ADPr-Ub reader through non-hydrolysable ubiquitinated ADP-ribose 0.47
The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI 0.20
5 0.77
High-resolution single-cell mapping of clonal hematopoiesis and structural variation in aplastic anemia 0.09
Biallelic variants in cause the most prevalent known recessive neurodevelopmental disorder 0.23
A repeat expansion in is a major risk factor for atypical frontotemporal lobar degeneration with ubiquitin-positive inclusions 0.03
De novo and inherited dominant variants in U4 and U6 snRNA genes cause retinitis pigmentosa 0.14
Tamoxifen induces PI3K activation in uterine cancer 0.26
11 3.16
Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial 0.03
Targeted therapies plus radiotherapy for diffuse intrinsic pontine glioma: the randomized phase 2 BIOMEDE trial 0.03
Cibisatamab and FAP-4-1BBL in microsatellite-stable colorectal cancer: a phase 1b trial 0.05
Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial 0.25
AI-based triage and decision support in mammography and digital tomosynthesis for breast cancer screening: a paired, noninferiority trial 0.20
Ipilimumab and nivolumab followed by chemoradiotherapy as bladder-sparing treatment in muscle-invasive bladder cancer: a phase 2 trial 0.80
Repotrectinib in NTRK fusion–positive advanced solid tumors: a phase 1/2 trial 0.04
Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial 0.69
Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial 0.04
Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial 0.03
Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer: circulating tumor DNA analysis of a randomized phase 3 trial 1.00
1 0.02
TDP-43 loss induces cryptic polyadenylation in ALS/FTD 0.02
1 0.60
Mechanistic dissection of GRHL2 and PR transcriptional co-regulation in breast cells 0.60
8 2.42
Non-cell-autonomous mechanisms of tumor initiation and relapse by chromosomal instability 1.00
Restoring the 14-3-3/CRAF regulatory interaction in Noonan syndrome using molecular glues 0.38
Distinct transcription factor interactions drive HOXB13 activity in different stages of prostate cancer 0.04
The liver talks back: NPY orchestrates attraction of cancer cells and CHK2-dependent clonogenicity in the metastatic niche 0.05
p53 regulates the expression of histone modifiers to restrict stemness and maintain differentiated luminal identity in breast cancer 0.20
CRISPR screens identify the ATPase VCP as a druggable therapeutic vulnerability in cholangiocarcinoma 0.21
G-quadruplexes as a source of vulnerability in BRCA2-deficient granule cell progenitors and medulloblastoma 0.04
TRIM24 as a therapeutic target in endocrine treatment–resistant breast cancer 0.50
6 3.53
One-year Follow-up after US-guided Transperineal Focal Laser Ablation of Localized Prostate Cancer: Worldwide Registry Study. 0.27
Cross-National Radiomics Validation Using Mammography to Predict Occult Invasion in Ductal Carcinoma in Situ. 0.35
Tumor Involvement of the Nipple at Preoperative Contrast-enhanced Mammography: A Multicenter Diagnostic Accuracy Study. 0.07
External Test of a Deep Learning Algorithm for Pulmonary Nodule Malignancy Risk Stratification Using European Screening Data. 0.83
AI Should Read Mammograms Only When Confident: A Hybrid Breast Cancer Screening Reading Strategy. 1.00
Percutaneous Thermal Ablation for Early-Stage Breast Cancer: An Open-Label, Randomized, Phase II Trial to Select the Preferred Technique for Evaluating Thermal Ablation as a Surgical Alternative. 1.00
4 0.87
Jagged1 regulates extracellular matrix deposition and remodeling in triple-negative breast cancer 0.08
Chromosomal instability shapes the tumor microenvironment of esophageal adenocarcinoma via a cGAS–chemokine–myeloid axis 0.06
Lifecourse genome-wide association study meta-analysis refines the critical life stages for adiposity’s influence on breast cancer risk 0.20
Systemically inducing trained immunity overcomes solid tumors’ immunosuppressive microenvironment 0.53
1 0.08
Cancer outcomes in women without upfront surgery for ductal carcinoma in situ: observational cohort study 0.08
3 1.12
Chromosomal instability promotes cell migration and invasion via EFEMP1 secretion into extracellular vesicles 0.94
TXNIP mediates LAT1/SLC7A5 endocytosis to limit amino acid uptake in cells entering quiescence 0.02
Parp7 generates an ADP-ribosyl degron that controls negative feedback of androgen signaling. 0.15
7 0.37
Long-term effects of colonoscopy screening on colorectal cancer incidence and mortality: a multicountry, population-based randomised controlled trial 0.09
Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study 0.03
Pimicotinib versus placebo for tenosynovial giant cell tumour (MANEUVER): an international, randomised, placebo-controlled, phase 3 trial 0.04
Interval cancer, sensitivity, and specificity comparing AI-supported mammography screening with standard double reading without AI in the MASAI study: a randomised, controlled, non-inferiority, single-blinded, population-based, screening-accuracy trial 0.04
Efficacy and safety of REGN9933A2 and REGN7508Cat for preventing postoperative venous thromboembolism (ROXI-VTE-I and ROXI-VTE-II): two randomised, open-label, phase 2 trials 0.06
Global variation in patterns of care and time to initial treatment for breast, cervical, and ovarian cancer from 2015 to 2018 (VENUSCANCER): a secondary analysis of individual records for 275 792 women from 103 population-based cancer registries in 39 countries and territories 0.05
Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial 0.04
16 7.10
Lymph node surgery and CDK4/6 inhibitors in early breast cancer: a pooled analysis from five randomised trials 0.30
[177Lu]Lu-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study 0.86
Neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by adjuvant pembrolizumab, in patients with muscle-invasive bladder cancer (SURE-02): a single-arm, phase 2 study 0.05
MRI-based personalisation of neoadjuvant chemotherapy duration in HER2-positive early breast cancer (TRAIN-3): primary results from a multicentre, single-arm, phase 2 study 1.00
Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial 0.03
Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial 0.77
Oncological outcomes with and without axillary lymph node dissection in patients with residual micrometastases after neoadjuvant chemotherapy (OPBC-07/microNAC): an international, retrospective cohort study 0.01
Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial 0.28
Pembrolizumab plus lenvatinib as second-line treatment in patients with pleural mesothelioma (PEMMELA): cohort 2 of a single-arm, phase 2 study 1.00
A prognostic classification system for extent of resection in IDH-mutant grade 2 glioma: an international, multicentre, retrospective cohort study with external validation by the RANO resect group 0.08
Artificial intelligence and radiologists in pancreatic cancer detection using standard of care CT scans (PANORAMA): an international, paired, non-inferiority, confirmatory, observational study 0.46
Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial 0.03
Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial 1.00
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial 0.41
Long-term survival and cure fraction estimates for paediatric central nervous system tumours in 31 European countries (EUROCARE-6): a population-based study 0.80
Hormone therapy use and young-onset breast cancer: a pooled analysis of prospective cohorts included in the Premenopausal Breast Cancer Collaborative Group 0.02
8 0.58
Talquetamab–Daratumumab in Relapsed or Refractory Myeloma 0.02
Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy 0.06
First-Line Zongertinib in Advanced HER2-Mutant Non–Small-Cell Lung Cancer 0.08
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma 0.05
Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab 0.03
Ten-Year Survival after Postmastectomy Chest-Wall Irradiation in Breast Cancer 0.09
European Study of Prostate Cancer Screening — 23-Year Follow-up 0.22
Sevabertinib in Advanced HER2-Mutant Non–Small-Cell Lung Cancer 0.03
1 1.00
Sex-based differences in effectiveness of immune checkpoint inhibitors in the treatment of advanced non-small-cell lung cancer: systematic review and meta-analysis 1.00

Numerical information only (in the tables above) is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International.